Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
1.278 Leser
Artikel bewerten:
(2)

EQS-Adhoc: Medacta Group SA: Medacta announces pay cuts to BoD and GEM members and publishes 2020 AGM invitation

Finanznachrichten News

DJ EQS-Adhoc: Medacta announces pay cuts to BoD and GEM members and publishes 2020 AGM invitation

EQS Group-Ad-hoc: Medacta Group SA / Key word(s): AGMEGM 
Medacta announces pay cuts to BoD and GEM members and publishes 2020 AGM 
invitation 
 
17-Apr-2020 / 19:48 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
 
*Press Release * 
 
*Medacta announces pay cuts to Board of Directors and Group Executive 
Management members and publishes 2020 AGM invitation* 
 
*- BOD and GEM decided voluntary to reduce their 2020 annual compensation to 
soften the economic impact of the Coronavirus pandemic;* 
 
*- Annual General Meeting (AGM) will take place on 19 May 2020 at the 
headquarters in Castel San Pietro, Switzerland, in accordance with the 
COVID-19-Ordinance 2. * 
 
_CASTEL SAN PIETRO_, _17 April 2020_ - _Ing. Francesco Siccardi, CEO of 
Medacta, says "The COVID-19 Outbreak is heavily impacting all of us and is 
rapidly evolving around the world, we must respond to this Coronavirus 
pandemic with every action within our control to protect our business. In 
this regard, I would like to thank our members of the Board of Directors 
(BoD) and Group Executive Management (GEM) to agree in reducing their 2020 
compensation and further extend the measures in place to fight this crisis". 
_ 
 
*2020 pay cuts to Board of Directors and Group Executive Management members* 
To further respond at the pandemic and soften the financial impact in our 
business, both the Board of Directors and the Group Executive Management 
decided to cut their 2020 total compensation. 
 
Our Founder and Chairman of the BoD, Dr. Alberto Siccardi and our Chief 
Executive Officer Ing. Francesco Siccardi decided to reduce their 2020 total 
compensation by 50%. The other members of the BoD and GEM will reduce their 
total compensation by 20%. 
 
*Medacta publishes 2020 AGM invitation* 
Medacta Group SA will hold its AGM on 19 May 2020 in accordance with the 
provisions as stipulated in the Ordinance of the Federal Council of 
Switzerland on the policies for fighting the coronavirus (COVID-19-Ordinance 
2). Accordingly, shareholders are not allowed to attend the Annual General 
Meeting in person. Shareholders will only be able to vote their shares by 
giving a power of attorney and related voting instructions to the 
independent proxy, either by returning the proxy form or by exercising their 
voting rights online as per the instructions provided in the invitation 
letter. 
 
The Board is proposing the re-election of Dr. Alberto Siccardi as Chairman 
of the Board of Directors. All current board members stand for re-election, 
except for Mr. Marco Gadola as previously communicated. 
 
The Board is also proposing the election of the members of the Remuneration 
Committee and the approval of the compensation for the member of the Board 
of Directors and the Group Executive Management. Further motions include the 
election for the financial year 2020 of the Independent Proxy Holder and 
Auditors. 
 
All details on the motions can be found in the invitation to the Annual 
General Meeting 2020 at 
https://www.medacta.com/EN/agm [1]. 
 
*Contact* 
Medacta Group SA 
Corrado Farsetta, CFO 
Phone: +41 91 696 60 60 
investor.relations@medacta.ch 
 
*About Medacta:* 
Medacta is an international company specializing in the design and 
production of innovative orthopaedic products and the development of 
accompanying surgical techniques for joint replacement, spine surgery, and 
sports medicine. Established in 1999 in Switzerland, Medacta's products and 
surgical techniques are characterized by innovation. Medacta is a pioneer in 
developing new offerings on the basis of minimally invasive surgical 
techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS") 
technique for hip replacements. Medacta has leveraged its orthopaedic 
expertise and comprehensive understanding of the human body to develop the 
sophisticated "_MySolutions_" technology, which offers surgeons highly 
personalized pre-operative planning and implant placement methodologies by 
creating advanced personalized kinematic models and 3D planning tools for 
use in hip, knee, shoulder and spine procedures. 
 
End of ad hoc announcement 
Language:    English 
Company:     Medacta Group SA 
             Strada Regina 
             6874 Castel San Pietro 
             Switzerland 
Phone:       +41 91 696 6060 
E-mail:      info@medacta.ch, investor.relations@medacta.ch 
Internet:    www.medacta.com 
ISIN:        CH0468525222 
Listed:      SIX Swiss Exchange 
EQS News ID: 1024541 
 
End of Announcement EQS Group News Service 
 
1024541 17-Apr-2020 CET/CEST 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=acdad2a9c03bb1e0d5f646d648b76785&application_id=1024541&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

April 17, 2020 13:49 ET (17:49 GMT)

© 2020 Dow Jones News
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.